An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus
designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in …

Background Repurposing broad-spectrum antivirals is an immediate treatment opportunity
for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for …

Abstract The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the
researchers to strive to develop drugs or vaccines to prevent or halt the progression of this …

Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in
clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a …

Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …

Introduction At this time, there is no specific therapeutic or vaccine for treatment of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for …

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …

Background Favipiravir possesses high utility for treating patients with COVID-19. However,
research examining the efficacy and safety of favipiravir for patients with COVID-19 is …